Clinical Trial

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Study acronym: DTP
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2019-01-25; most recent amendment 2026-04-17.
Status change: Recruiting → Active, Not Recruiting 2025-03-07
Status change: Not Yet Recruiting → Recruiting 2020-05-13
Trial Details
NCT Number NCT03820141
Lead Sponsor The Methodist Hospital Research Institute
Collaborators: AstraZeneca
Conditions Breast Cancer
Enrollment 51 participants
Start Date 2020-06-30
Primary Completion 2024-10-30 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-20